GDUFA Type II API DMF Submissions Signal Generics Pipeline Shift

FDA's latest GDUFA Type II API Drug Master File payment receipts data reveals a measurable contraction in submission activity through the first half of FY 2026, a trend that carries direct implications for generics manufacturers managing API sourcing strategies and ANDA pipeline timelines. With only 147 payments recorded through May of FY 2026, compared to 385 in FY 2023 and 370 in FY 2025, the trajectory warrants close attention from regulatory affairs leads and supply chain planners alike.

The FDA's DMF Payments Received table tracks total monthly counts of GDUFA Type II API DMF payments by month and fiscal year as received by the agency. The figures are subject to change due to refunds or other payment issues. FY 2023 closed with 385 total payments, FY 2024 with 263, FY 2025 with 370, and FY 2026 has recorded 147 payments across October through May. The FY 2024 dip followed by a FY 2025 rebound suggests cyclical variation, but the current FY 2026 pace, if sustained, would fall short of recent full-year totals.

Monthly distribution patterns add further context. September has historically driven outsized volume: FY 2023 closed with 103 payments in that month alone, while FY 2024 recorded 80 in September and FY 2025 recorded 48. This end-of-fiscal-year clustering is consistent with deadline-driven submission behavior. QA directors and regulatory leads should account for this pattern when benchmarking current FY 2026 figures, which reflect only partial-year data. April and March showed relative strength in FY 2026, at 31 and 30 payments respectively, suggesting some pipeline activity remains active in those months.

For plant heads and API sourcing teams, declining or shifting DMF submission volumes can indicate reduced new API supplier qualification activity, consolidation among CDMOs, or a recalibration of generics development priorities. Under 21 CFR Part 314 and ICH Q10 frameworks, robust DMF documentation underpins process validation and sterility assurance commitments across the supply chain. Shifts in DMF filing behavior upstream can propagate into ANDA review timelines and ultimately affect product availability.

Source: FDA GDUFA Type II API DMF Payment Receipts Report, published May 4, 2026, via FDA What's New: Drugs RSS Feed.